Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Escudier, B.; Motzer, R. J.; Dyer, M.; May, J. R.; Ejzykowicz, F.; Kurt, M.; Lee, C. W.; Wang, P.; Testa, E.; Sharpe, D. J.; George, S.; Tannir, N. |
| Abstract Title: | Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC) |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1212 |
| Language: | English |
| ACCESSION: | WOS:000866211602013 |
| DOI: | 10.1016/j.annonc.2022.07.1562 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1459P -- Source: Wos |
